Arbutus Biopharma Corp (I9DN)

Frankfurt
Currency in EUR
2.886
+0.110(+3.96%)
Closed·
I9DN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
2.8862.886
52 wk Range
2.4464.222
Key Statistics
Edit
Bid/Ask
2.85 / 2.948
Prev. Close
2.776
Open
2.886
Day's Range
2.886-2.886
52 wk Range
2.446-4.222
Volume
-
Average Volume (3m)
1.35K
1-Year Change
15.35%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
I9DN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Compare I9DN to Peers and Sector

Metrics to compare
I9DN
Peers
Sector
Relationship
P/E Ratio
−9.0x−4.2x−0.5x
PEG Ratio
−0.67−0.060.00
Price/Book
6.5x1.9x2.6x
Price / LTM Sales
102.1x6.7x2.9x
Upside (Analyst Target)
-160.2%54.5%
Fair Value Upside
Unlock19.6%8.5%Unlock

Earnings

Latest Release
Mar 27, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
1.57M / --
EPS Revisions
Last 90 days

People Also Watch

14.72
IMVT
-2.32%
6.540
IREN
+3.81%
22.380
RKLB
+2.29%
8.58
LUNR
+2.39%
7.530
QBTS
+2.45%

FAQ

What Is the Arbutus Biopharma (I9DN) Stock Price Today?

The Arbutus Biopharma stock price today is 2.886

What Stock Exchange Does Arbutus Biopharma Trade On?

Arbutus Biopharma is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for Arbutus Biopharma?

The stock symbol for Arbutus Biopharma is "I9DN."

What Is the Arbutus Biopharma Market Cap?

As of today, Arbutus Biopharma market cap is 554.25M.

What is Arbutus Biopharma Earnings Per Share?

The Arbutus Biopharma EPS is -0.38.

From a Technical Analysis Perspective, Is I9DN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.